SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001850
Filing Date
2024-11-12
Accepted
2024-11-12 08:18:01
Documents
78
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240930x10q.htm   iXBRL 10-Q 1789711
2 EX-31.1 tmb-20240930xex31d1.htm EX-31.1 13159
3 EX-32.1 tmb-20240930xex32d1.htm EX-32.1 6188
4 GRAPHIC tmb-20240930x10q001.jpg GRAPHIC 43242
  Complete submission text file 0001410578-24-001850.txt   7634693

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20240930.xsd EX-101.SCH 55659
6 EX-101.CAL tmb-20240930_cal.xml EX-101.CAL 57181
7 EX-101.DEF tmb-20240930_def.xml EX-101.DEF 231363
8 EX-101.LAB tmb-20240930_lab.xml EX-101.LAB 455745
9 EX-101.PRE tmb-20240930_pre.xml EX-101.PRE 358244
81 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240930x10q_htm.xml XML 1214530
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 241443660
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)